Elsevier

Neuropharmacology

Volume 36, Issues 11–12, November–December 1997, Pages 1733-1739
Neuropharmacology

MKC-242, a novel 5-HT1A receptor agonist, facilitates cortical acetylcholine release by a mechanism different from that of 8-OH-DPAT in awake rats

https://doi.org/10.1016/S0028-3908(97)00174-3Get rights and content

Abstract

We have previously reported that 5-{3-[((2S)-1,4-benzodioxan-2-ylmethyl)amino]propoxy}-1,3-benzodioxole (MKC-242), a potent and selective serotonin (5-HT)1A receptor agonist, exerts anxiolytic- and antidepressant-like effects in animal models and that the antidepressant-like effect may be mediated by postsynaptic 5-HT1A receptors. The present study, using a microdialysis technique, was undertaken to characterize in vivo the effect of MKC-242 on cholinergic neurons. Subcutaneous injection of MKC-242 (0.5–1.0 mg/kg), like the typical 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), increased extracellular acetylcholine (ACh) levels in the rat cerebral cortex. The increase in ACh release by MKC-242 was also observed in the hippocampus. The effect of MKC-242 on cortical ACh release was attenuated by pretreatment with the 5-HT1A receptor antagonists (10 mg/kg, s.c.) propranolol and N-tert-butyl-3-(4-(2-methoxyphenyl)piperazin-1-yl)-2-phenylpropanamide. The increase in cortical ACh release by MKC-242 was blocked by lesion of serotonergic neurons with 5,7-dihydroxytryptamine, whereas that by 8-OH-DPAT was not. Lesion of noradrenergic neurons with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine did not affect the MKC-242-induced increase in ACh release. These results suggest that systemic injection of MKC-242 facilitates in vivo ACh release via an activation of somadendritic 5-HT1A autoreceptors, and that MKC-242 and 8-OH-DPAT affect cholinergic neurons in the rat cerebral cortex via different mechanisms.

References (38)

  • T. Matsuda et al.

    Novel benzodioxan derivative, 5-(3-[((2S)-1, 4-benzodioxan-2-rylmethyl)amino]propoxy)-1,3-benzodioxole HC1 (MKC-242), with a highly potent and selective agonist activity at rat central serotonin1A receptors

    Japanese Journal of Pharmacology

    (1995)
  • G. Maura et al.

    Cholinergic terminals in rat hippocampus possess 5-HT1B receptors mediating inhibition of acetylcholine release

    European Journal of Pharmacology

    (1986)
  • G. Maura et al.

    Acetylcholine release from rat hippocampal slices is modulated by 5-hydroxytryptamine

    European Journal of Pharmacology

    (1989)
  • M.J. Millan et al.

    α2 receptors mediate the antinociceptive action of 8-OH-DPAT in the hot-plate test in mice

    Brain Research

    (1991)
  • O.G. Nilsson et al.

    Acetylcho-line release in the hippocampus, regulation by monoaminergic afferents as assessed by in vivo microdialysis

    Brain Research

    (1992)
  • T. Ohue et al.

    Regulation of acetylcholine release in vivo from rat hippocampus by monoamines as revealed by novel column-switching HPLC with electrochemical detection

    Brain Research

    (1992)
  • R. Quirion et al.

    Evidence for the existence of serotonin type-2 receptors on cholinergic terminals in rat cortex

    Brain Research

    (1985)
  • A. Siniscalchi et al.

    Different effects of 8-OH-DPAT, a 5-HT1A receptor agonist, on cortical acetylcholine release, electrocortigram and body temperature in guinea pigs and rats

    European Journal of Pharmacology

    (1990)
  • S. Tellez et al.

    The α2-adrenoceptor antagonist, (+)-efaroxan, enhances acetylcho-line release in the rat cortex in vivo

    European Journal of Pharmacology

    (1995)
  • Cited by (27)

    • NLX-101, a cortical 5-HT<inf>1A</inf> receptor biased agonist, reverses scopolamine-induced deficit in the delayed non-matching to position model of cognition

      2021, Brain Research
      Citation Excerpt :

      Thus, 8-OH-DPAT increases extracellular levels of acetylcholine (ACh) in the rat and guinea pig cortex, albeit with less efficacy in the latter species (Bianchi et al., 1990; Siniscalchi et al., 1990). This enhancing effect is shared by other 5-HT1A receptor agonists, MKC-242 or repinotan (a.k.a. BAYx3702) (Koyama et al., 1999; Somboonthum et al., 1997). Of note, the enhanced ACh efflux induced by repinotan was abrogated by WAY-100,635.

    • Psychopharmacology of combined activation of the serotonin<inf>1A</inf> and σ<inf>1</inf> receptors

      2017, European Journal of Pharmacology
      Citation Excerpt :

      Activation of 5-HT1A receptors affects the release of several neurotransmitters (noradrenaline, dopamine and acetylcholine) beside 5-HT. The regulation of 5-HT (Hjorth and Magnusson, 1988; Sharp et al., 1989) and acetylcholine (Somboonthum et al., 1997) is mainly mediated by presynaptic 5-HT1A receptors and that of noradrenaline (Suzuki et al., 1995; Hajós-Korcsok et al., 1999) or dopamine (Sakaue et al., 2000; Ago et al., 2003) release is mediated by postsynaptic 5-HT1A receptors. Systemic administration of 5-HT1A receptor agonists inhibits anxiety-like and depression-like behaviors, aggressive and obsessive-compulsive behaviors.

    View all citing articles on Scopus
    View full text